Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis

Tuberculosis (TB), a common condition worldwide, is still among the main infectious diseases with high mortality rates, both in adults and infants. Drug-resistant tuberculosis (DR-TB) drugs, revised by the World Health Organization (WHO) in 2018, are a prolonged and complex therapy associated with m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pneumologia 2022-10, Vol.70 (3), p.117-126
Hauptverfasser: Grosu-Creangă, Ionela-Alina, Trofor, Antigona Carmen, Crișan-Dabija, Radu Adrian, Robu-Popa, Daniela, Ghiciuc, Cristina Mihaela, Lupușoru, Elena Cătălina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 126
container_issue 3
container_start_page 117
container_title Pneumologia
container_volume 70
creator Grosu-Creangă, Ionela-Alina
Trofor, Antigona Carmen
Crișan-Dabija, Radu Adrian
Robu-Popa, Daniela
Ghiciuc, Cristina Mihaela
Lupușoru, Elena Cătălina
description Tuberculosis (TB), a common condition worldwide, is still among the main infectious diseases with high mortality rates, both in adults and infants. Drug-resistant tuberculosis (DR-TB) drugs, revised by the World Health Organization (WHO) in 2018, are a prolonged and complex therapy associated with many adverse drug effects (ADEs). To systematically review the ADEs of second-line anti-TB drugs reported in multicentric studies published after the latest WHO guidelines, compared with those from clinical trials published before 2018. A PubMed search, using keywords (TB OR DR-TB) AND (adverse effects) AND “second-line anti-TB drugs”, resulted in 56 studies. Only two studies, published after the last update of WHO guidelines in 2018, reported ADEs. A total of 223 participants were included in the two selected studies. The use of multidrug regimens has been associated with an increased incidence of ADEs: 42 ADEs were recorded in 30 patients (26.3%) in the first study, while all patients had at least one ADE that occurred or worsened during treatment; and 19 (17%) had severe ADEs in the second study. However, both studies had a good favourable outcome rate (90% and 79.8%, respectively). Gastrointestinal disturbances, hepatotoxicity, headache and dizziness are the most common ADEs induced by a majority of second-line DR-TB treatments. A special attention should be given in the case of association of drugs determining QT interval (QT) prolongation on electrocardiogram, or psychiatric disorders. Proper strategies about ADE management have to be planned for timely detection of the possible ADEs that can be induced by second-line anti-TB therapy.
doi_str_mv 10.2478/pneum-2022-0029
format Article
fullrecord <record><control><sourceid>walterdegruyter_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2478_pneum_2022_0029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2478_pneum_2022_0029703117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1357-5e585e22bd8a019df8bf612b798ceb028a961354ea5c1ca85b6f768ee179d33</originalsourceid><addsrcrecordid>eNp1kM1KAzEUhYMoWGrXbvMCY5NMM8kILkpRKxS6UNDdkJ-bMjLNlCSj9D18YNPWRTeu7uFwzsflIHRLyR2bCTndeRi2BSOMFYSw-gKNWPYLwuuPyzN9jSYxtpqUM06l5GKEfub2C0IEDM6BSRG33g4GLNZ7HMH03hZd6wErn9o0aAhm6PrYRmzDsIn32cfDzqoEWKuYa73HnYoJvy_XOAVQaQs-4ZBJ26xysO19xK4PR0ARILNShuNz-A26cqqLMPm7Y_T69Pi2WBar9fPLYr4qDC25KDhwyYExbaUitLZOaldRpkUtDWjCpKqrHJyB4oYaJbmunKgkABW1Lcsxmp6oJvQxBnDNLrRbFfYNJc1h1ea4anNYtTmsmhsPp8a36hIEC5sw7LNoPvsh-Pzpf01BSkpF-Qu8z4T5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis</title><source>Walter De Gruyter: Open Access Journals</source><creator>Grosu-Creangă, Ionela-Alina ; Trofor, Antigona Carmen ; Crișan-Dabija, Radu Adrian ; Robu-Popa, Daniela ; Ghiciuc, Cristina Mihaela ; Lupușoru, Elena Cătălina</creator><creatorcontrib>Grosu-Creangă, Ionela-Alina ; Trofor, Antigona Carmen ; Crișan-Dabija, Radu Adrian ; Robu-Popa, Daniela ; Ghiciuc, Cristina Mihaela ; Lupușoru, Elena Cătălina</creatorcontrib><description>Tuberculosis (TB), a common condition worldwide, is still among the main infectious diseases with high mortality rates, both in adults and infants. Drug-resistant tuberculosis (DR-TB) drugs, revised by the World Health Organization (WHO) in 2018, are a prolonged and complex therapy associated with many adverse drug effects (ADEs). To systematically review the ADEs of second-line anti-TB drugs reported in multicentric studies published after the latest WHO guidelines, compared with those from clinical trials published before 2018. A PubMed search, using keywords (TB OR DR-TB) AND (adverse effects) AND “second-line anti-TB drugs”, resulted in 56 studies. Only two studies, published after the last update of WHO guidelines in 2018, reported ADEs. A total of 223 participants were included in the two selected studies. The use of multidrug regimens has been associated with an increased incidence of ADEs: 42 ADEs were recorded in 30 patients (26.3%) in the first study, while all patients had at least one ADE that occurred or worsened during treatment; and 19 (17%) had severe ADEs in the second study. However, both studies had a good favourable outcome rate (90% and 79.8%, respectively). Gastrointestinal disturbances, hepatotoxicity, headache and dizziness are the most common ADEs induced by a majority of second-line DR-TB treatments. A special attention should be given in the case of association of drugs determining QT interval (QT) prolongation on electrocardiogram, or psychiatric disorders. Proper strategies about ADE management have to be planned for timely detection of the possible ADEs that can be induced by second-line anti-TB therapy.</description><identifier>ISSN: 2247-059X</identifier><identifier>EISSN: 2247-059X</identifier><identifier>DOI: 10.2478/pneum-2022-0029</identifier><language>eng</language><publisher>Sciendo</publisher><subject>adverse drug effects ; DR-TB ; second-line drugs</subject><ispartof>Pneumologia, 2022-10, Vol.70 (3), p.117-126</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1357-5e585e22bd8a019df8bf612b798ceb028a961354ea5c1ca85b6f768ee179d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://sciendo.com/pdf/10.2478/pneum-2022-0029$$EPDF$$P50$$Gwalterdegruyter$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://sciendo.com/article/10.2478/pneum-2022-0029$$EHTML$$P50$$Gwalterdegruyter$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,27924,27925,76164,76165</link.rule.ids></links><search><creatorcontrib>Grosu-Creangă, Ionela-Alina</creatorcontrib><creatorcontrib>Trofor, Antigona Carmen</creatorcontrib><creatorcontrib>Crișan-Dabija, Radu Adrian</creatorcontrib><creatorcontrib>Robu-Popa, Daniela</creatorcontrib><creatorcontrib>Ghiciuc, Cristina Mihaela</creatorcontrib><creatorcontrib>Lupușoru, Elena Cătălina</creatorcontrib><title>Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis</title><title>Pneumologia</title><description>Tuberculosis (TB), a common condition worldwide, is still among the main infectious diseases with high mortality rates, both in adults and infants. Drug-resistant tuberculosis (DR-TB) drugs, revised by the World Health Organization (WHO) in 2018, are a prolonged and complex therapy associated with many adverse drug effects (ADEs). To systematically review the ADEs of second-line anti-TB drugs reported in multicentric studies published after the latest WHO guidelines, compared with those from clinical trials published before 2018. A PubMed search, using keywords (TB OR DR-TB) AND (adverse effects) AND “second-line anti-TB drugs”, resulted in 56 studies. Only two studies, published after the last update of WHO guidelines in 2018, reported ADEs. A total of 223 participants were included in the two selected studies. The use of multidrug regimens has been associated with an increased incidence of ADEs: 42 ADEs were recorded in 30 patients (26.3%) in the first study, while all patients had at least one ADE that occurred or worsened during treatment; and 19 (17%) had severe ADEs in the second study. However, both studies had a good favourable outcome rate (90% and 79.8%, respectively). Gastrointestinal disturbances, hepatotoxicity, headache and dizziness are the most common ADEs induced by a majority of second-line DR-TB treatments. A special attention should be given in the case of association of drugs determining QT interval (QT) prolongation on electrocardiogram, or psychiatric disorders. Proper strategies about ADE management have to be planned for timely detection of the possible ADEs that can be induced by second-line anti-TB therapy.</description><subject>adverse drug effects</subject><subject>DR-TB</subject><subject>second-line drugs</subject><issn>2247-059X</issn><issn>2247-059X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEUhYMoWGrXbvMCY5NMM8kILkpRKxS6UNDdkJ-bMjLNlCSj9D18YNPWRTeu7uFwzsflIHRLyR2bCTndeRi2BSOMFYSw-gKNWPYLwuuPyzN9jSYxtpqUM06l5GKEfub2C0IEDM6BSRG33g4GLNZ7HMH03hZd6wErn9o0aAhm6PrYRmzDsIn32cfDzqoEWKuYa73HnYoJvy_XOAVQaQs-4ZBJ26xysO19xK4PR0ARILNShuNz-A26cqqLMPm7Y_T69Pi2WBar9fPLYr4qDC25KDhwyYExbaUitLZOaldRpkUtDWjCpKqrHJyB4oYaJbmunKgkABW1Lcsxmp6oJvQxBnDNLrRbFfYNJc1h1ea4anNYtTmsmhsPp8a36hIEC5sw7LNoPvsh-Pzpf01BSkpF-Qu8z4T5</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Grosu-Creangă, Ionela-Alina</creator><creator>Trofor, Antigona Carmen</creator><creator>Crișan-Dabija, Radu Adrian</creator><creator>Robu-Popa, Daniela</creator><creator>Ghiciuc, Cristina Mihaela</creator><creator>Lupușoru, Elena Cătălina</creator><general>Sciendo</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221001</creationdate><title>Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis</title><author>Grosu-Creangă, Ionela-Alina ; Trofor, Antigona Carmen ; Crișan-Dabija, Radu Adrian ; Robu-Popa, Daniela ; Ghiciuc, Cristina Mihaela ; Lupușoru, Elena Cătălina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1357-5e585e22bd8a019df8bf612b798ceb028a961354ea5c1ca85b6f768ee179d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>adverse drug effects</topic><topic>DR-TB</topic><topic>second-line drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grosu-Creangă, Ionela-Alina</creatorcontrib><creatorcontrib>Trofor, Antigona Carmen</creatorcontrib><creatorcontrib>Crișan-Dabija, Radu Adrian</creatorcontrib><creatorcontrib>Robu-Popa, Daniela</creatorcontrib><creatorcontrib>Ghiciuc, Cristina Mihaela</creatorcontrib><creatorcontrib>Lupușoru, Elena Cătălina</creatorcontrib><collection>CrossRef</collection><jtitle>Pneumologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grosu-Creangă, Ionela-Alina</au><au>Trofor, Antigona Carmen</au><au>Crișan-Dabija, Radu Adrian</au><au>Robu-Popa, Daniela</au><au>Ghiciuc, Cristina Mihaela</au><au>Lupușoru, Elena Cătălina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis</atitle><jtitle>Pneumologia</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>70</volume><issue>3</issue><spage>117</spage><epage>126</epage><pages>117-126</pages><issn>2247-059X</issn><eissn>2247-059X</eissn><abstract>Tuberculosis (TB), a common condition worldwide, is still among the main infectious diseases with high mortality rates, both in adults and infants. Drug-resistant tuberculosis (DR-TB) drugs, revised by the World Health Organization (WHO) in 2018, are a prolonged and complex therapy associated with many adverse drug effects (ADEs). To systematically review the ADEs of second-line anti-TB drugs reported in multicentric studies published after the latest WHO guidelines, compared with those from clinical trials published before 2018. A PubMed search, using keywords (TB OR DR-TB) AND (adverse effects) AND “second-line anti-TB drugs”, resulted in 56 studies. Only two studies, published after the last update of WHO guidelines in 2018, reported ADEs. A total of 223 participants were included in the two selected studies. The use of multidrug regimens has been associated with an increased incidence of ADEs: 42 ADEs were recorded in 30 patients (26.3%) in the first study, while all patients had at least one ADE that occurred or worsened during treatment; and 19 (17%) had severe ADEs in the second study. However, both studies had a good favourable outcome rate (90% and 79.8%, respectively). Gastrointestinal disturbances, hepatotoxicity, headache and dizziness are the most common ADEs induced by a majority of second-line DR-TB treatments. A special attention should be given in the case of association of drugs determining QT interval (QT) prolongation on electrocardiogram, or psychiatric disorders. Proper strategies about ADE management have to be planned for timely detection of the possible ADEs that can be induced by second-line anti-TB therapy.</abstract><pub>Sciendo</pub><doi>10.2478/pneum-2022-0029</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2247-059X
ispartof Pneumologia, 2022-10, Vol.70 (3), p.117-126
issn 2247-059X
2247-059X
language eng
recordid cdi_crossref_primary_10_2478_pneum_2022_0029
source Walter De Gruyter: Open Access Journals
subjects adverse drug effects
DR-TB
second-line drugs
title Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A09%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-walterdegruyter_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20effects%20induced%20by%20second-line%20antituberculosis%20drugs:%20an%20update%20based%20on%20last%20WHO%20treatment%20recommendations%20for%20drug-resistant%20tuberculosis&rft.jtitle=Pneumologia&rft.au=Grosu-Creang%C4%83,%20Ionela-Alina&rft.date=2022-10-01&rft.volume=70&rft.issue=3&rft.spage=117&rft.epage=126&rft.pages=117-126&rft.issn=2247-059X&rft.eissn=2247-059X&rft_id=info:doi/10.2478/pneum-2022-0029&rft_dat=%3Cwalterdegruyter_cross%3E10_2478_pneum_2022_0029703117%3C/walterdegruyter_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true